Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Mechanisms of Dupilumab in AERD - Effects on Aspirin Hypersensitivity Response, With a Focus on Innate Type 2 Inflammatory Responses

NCT05031455 is registered in ClinicalTrials.gov with Scripps Clinic as lead sponsor.

NCT NCT05031455
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05031455 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Mechanisms of Dupilumab in AERD - Effects on Aspirin Hypersensitivity Response, With a Focus on Innate Type 2 Inflammatory Responses
Lead sponsor
Scripps Clinic
Phase
Phase 2
Overall status
Completed
Start date
March 25, 2024
Completion date
April 20, 2026
Enrollment
16 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

aspirin-exacerbated respiratory disease